GE HealthCare Unveils AI-Enhanced Ultrasound for Dense Breast Cancer Detection

2025-03-21 digitalcare

Boston, Friday, 21 March 2025.
GE HealthCare has launched the Invenia ABUS Premium, an AI-driven 3D ultrasound system designed to enhance early detection of breast cancer, specifically in dense breast tissue, offering greater scanning efficiency and accuracy.

Addressing a Critical Healthcare Need

The launch of Invenia ABUS Premium on March 20, 2025, addresses a significant healthcare challenge, as approximately 71% of breast cancers occur in dense breasts, affecting 40% of women in general and 70% of Asian women specifically [1][2]. The technology arrives at a crucial time, as one-third of cancers in dense breasts currently go undetected by traditional mammograms [3], highlighting the urgent need for enhanced screening methods.

Advanced AI Integration

The system incorporates sophisticated AI features, including Verisound AI and AI Assistant, which enable immediate qualitative evaluation during examinations [4]. A notable advancement is the Fast Scan tool, which increases scanning efficiency by up to 40% while maintaining image quality [3][5]. The technology utilizes cSound Imageformer capabilities to automatically create focus at every pixel, ensuring consistent high-resolution imaging [6].

Patient-Centric Design

The Invenia ABUS Premium features a new Reverse Curve transducer that adapts to breast anatomy, offering selectable compression levels for personalized comfort [4]. This patient-friendly approach has shown remarkable acceptance rates, with studies indicating 100% of women would recommend an ABUS exam to others [3]. The system’s non-invasive design helps reduce unnecessary biopsies while avoiding ionizing radiation exposure [6].

Global Implementation and Future Impact

Following its FDA premarket approval, GE HealthCare plans to roll out the Invenia ABUS Premium across key countries throughout 2025 [4]. The technology has already garnered attention at the 2025 European Congress of Radiology and is scheduled for showcase at upcoming major medical conferences [6]. Healthcare professionals, including Dr. Athina Vourtsis, Chief Director of Athena Medical, have praised the system’s AI capabilities and improved image quality, noting its potential to enhance diagnostic confidence [3][4].

Bronnen

AI-driven breast cancer